CAR-T cancer treatment under scrutiny: could it trigger new tumors?
NCT ID NCT07378969
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study investigates whether the CAR-T cell therapy tisagenlecleucel may lead to new T-cell cancers in patients who received it. Researchers will analyze stored tumor and blood samples from 30 patients to look for signs that the therapy itself caused these secondary malignancies. The goal is to better understand the long-term safety of this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY MALIGNANCIES OF T-CELL ORIGIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGKurume, Fukuoka, 830-8543, Japan
-
Novartis Investigative Site
RECRUITINGOsaka, Osaka, 5418567, Japan
-
Novartis Investigative Site
RECRUITINGBunkyo Ku, Tokyo, 1138677, Japan
Conditions
Explore the condition pages connected to this study.